Results 151 to 160 of about 316,189 (194)

Subacute uremic and diabetic polyneuropathy

Muscle & Nerve, 1997
We present 4 patients who had a subacute, predominantly motor polyneuropathy associated with diabetes mellitus and end-stage renal disease. Electrophysiological studies and muscle biopsy indicated a primary axonal degeneration of nerve with secondary segmental demyelination, and mild to moderate, acute and chronic denervation of muscle.
C F, Bolton, M J, McKeown, R, Chen, B, Toth, H, Remtulla   +4 more
openaire   +2 more sources

New Insights Into Diabetic Polyneuropathy

JAMA, 2003
Patients with complaints of numbness, tingling, and dysesthesias in the toes and feet are frequently referred to neurologists. Often, the only objective evidence for peripheral nerve dysfunction in these patients is limited to small-caliber sensory nerve fibers.
Michael, Polydefkis, John W, Griffin, Justin, McArthur   +2 more
openaire   +2 more sources

Biomarkers for the Development and Progression of Diabetic Polyneuropathy

Neuroscience and Behavioral Physiology, 2020
To study the diagnostic potential of brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGFA) and their high affinity receptors (TrkB, VEGFR2) in the development and progression of diabetic polyneuropathy.The main group consisted of 65 patients with diabetes mellitus and confirmed DPN.
Yu V, Karakulova, T A, Filimonova
openaire   +2 more sources

Plasma Norepinephrine in Sensory Diabetic Polyneuropathy

Diabetes Care, 1993
OBJECTIVE To examine whether changes in circulating norepinephrine are associated with the sensory disturbances of diabetic polyneuropathy. Experimental studies have indicated that NE can excite sprouts from injured nerves, producing pain. RESEARCH DESIGN AND METHODS
Tsigos, Constantine, Reed, Paul, Weinkove, Cyril, White, Anne; id_orcid 0000-0002-7686-2884, Young, Robert J.   +4 more
openaire   +3 more sources

Epidemiology of polyneuropathy in diabetes and prediabetes

2014
Diabetic distal symmetric sensorimotor polyneuropathy (DSPN) represents a major health problem, associated with excruciating neuropathic pain, increased morbidity and impaired quality of life. The understanding of its epidemiology is difficult due to methodological issues.
Dan, Ziegler, Nikolaos, Papanas, Aaron I, Vinik, Jonathan E, Shaw   +3 more
openaire   +2 more sources

Strength–duration properties in diabetic polyneuropathy

Diabetes Research and Clinical Practice, 2007
We sought to examine the changes in the strength-duration time constant (SDTC) of the median nerve in diabetic polyneuropathy. The SDTC is a measure of axonal excitability and depends on the biophysical properties of the axonal membrane. It may provide some information about Na(+) channel functioning.
Yerdelen D., Koç F., Uysal H., Sarica Y.   +3 more
openaire   +3 more sources

Painful Diabetic Polyneuropathy

The Clinical Journal of Pain, 2012
To provide a current overview of the diagnostic work-up and management of painful diabetic polyneuropathy (PDPN).A review covering the literature from 2004 to 2011, which describes the tools designed to diagnose neuropathic pain and assess its severity, including self-administered questionnaires, validated laboratory tests and simple handheld screening
SPALLONE, VINCENZA, Lacerenza, M, Rossi, A, Sicuteri, R, Marchettini, P.   +4 more
openaire   +4 more sources

Clinical features of diabetic polyneuropathy

2014
Diabetic polyneuropathy (DPN) has several forms of clinical presentation. It may be asymptomatic, or present with prominent sensory symptoms, including neuropathic pain. Clinical neurologic examination is helpful in identifying patients with distal sensory deficits, loss of deep tendon reflexes, early distal motor abnormalities and skin ulceration ...
openaire   +2 more sources

Cocarnit in the treatment of diabetic polyneuropathy

Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2016
Study the effect of cocarnit on the peripheral nerve functions in patients with diabetic distal sensorimotor polyneuropathy (DDSP).Thirty patients with DDSP, aged from 27 to 65 years, mean 55.3±10.8 years, with diabetes mellitus duration from 2 to 20 years (mean 8.0±5.8 years) received cocarnit as monotherapy in dose of 2 ml daily during 9 days.
openaire   +2 more sources

Treatment of Diabetic Polyneuropathy

Annals of the New York Academy of Sciences, 2006
Abstract:  At least one of four diabetic patients is affected by distal symmetric polyneuropathy (DSP), which represents a major health problem, as it may present with partly excruciating neuropathic pain and is responsible for substantial morbidity, increased mortality, and impaired quality of life. Treatment is based on four cornerstones: (a) causal
openaire   +2 more sources